Full-Time
Process Support Engineering Lead IFF
All genders
Sanofi
10,001+ employees
Develops pharmaceuticals and vaccines globally
No salary listed
Senior
Frankfurt, Germany
- Experience in Pharmaceutical Process Engineering Tier 1 project > 50 m€
- Experience in managing Engineering contracts & facility start-up
- In depth knowledge in Chemistry processes including aseptic technologies
- Excellent problem solver and able to generate innovative digital solutions to improve efficiency
- Collaborate effectively across the organization and build strong relationships to positively impact project results
- Develop teams for future needs and translate business requirements into technical solutions
- Master’s degree in Chemical; Biotech Process Engineering or equivalent
- English (Project language), Other languages will be appreciated
- Design and Deliver all Support Process Engineering activities (Preparation, Tank Farm, Specific Operational Units like Solvent Recovery, …) from Basic Engineering to Detailed Design for the Program in accordance with EHS, Quality, Business & Users requirements focus on design to cost solutions & replication for Glargine in China
- Collaborate with transversal functions (EHS, Operations & Quality, procurement, legal and others) to manage basic engineering & Detailed Design studies with optimized solutions
- Lead Engineering contractor to deliver design on time in full & reach project objectives (User Requirement Specification, Layout, Design Specification, Piping & Instrumentation Diagram, Functional analysis for process control & supervision, , …)
- Define effective governance with the project team and strengthen leadership and organizational capabilities
- Anticipate, identify, and manage project risks by creating and tracking action plans, and communication to Process lead
- Build and sustain high performance team (internal & external)
- Provide technical support for commissioning (FAT/SAT) for the program in close collaboration with the C&Q leader
Sanofi provides healthcare solutions through the development of treatments and vaccines. The company focuses on research and development to create new medicines and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medications, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and extensive R&D efforts, supported by strategic partnerships and a diverse product pipeline. The company's goal is to enhance health outcomes and improve the quality of life for people globally by delivering effective and safe healthcare solutions.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Simplify's Take
What believers are saying
- Sanofi's Q1 2025 profit grew by 20%, driven by Dupixent and new launches.
- Tolebrutinib shows promise in treating non-relapsing secondary progressive multiple sclerosis.
- Sanofi's focus on R&D and strategic acquisitions strengthens its position in immunology.
What critics are saying
- Increased competition in multiple sclerosis market may impact Sanofi's market share.
- Potential regulatory delays for tolebrutinib could affect market entry timelines.
- Integration challenges from recent acquisitions may disrupt Sanofi's operations.
What makes Sanofi unique
- Sanofi's Sarclisa uses innovative on-body injector for multiple myeloma treatment.
- Acquisitions of Blueprint Medicines and Vigil Neuroscience expand Sanofi's rare disease portfolio.
- Dupixent is the first new targeted therapy for chronic spontaneous urticaria in a decade.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Professional Development Budget
Parental Leave
Company News
New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...
Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...
Innate Pharma announced a €15M investment by Sanofi, subscribing to 8,345,387 new shares at €1.7974 each. This capital increase supports their ongoing partnership, including the BCMA targeting ANKET® program. The investment will aid in extending Innate's cash runway for pipeline execution. The capital increase is expected to close on April 25, 2025, with shares trading on Euronext Paris the same day.
Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), up 20.1% year over year and 18.7% in constant currency. The company reported first-quarter sales of 9.89 billion euros ($10.42 billion), beating the consensus of $9.77 billion. This was driven by launches, Dupixent, and favorable Beyfortus phasing. Sales increased 10.8% year over year and 9.7% on constant currency. U.S. sales were 4.66 billion and increased by 15.4%